New approaches to mantle cell lymphoma – pro
Mantle cell lymphoma remains difficult to treat. There is an emerging consensus that autologous stem cell transplantation cannot compensate for an inadequate front line therapy. R-CHOP-like regimens, infusion or bolus based, can lead to complete response rates of approximately 40% and overall response rates of approximately 90% and, in spite of further consolidation with ASCT, most patients will eventually relapse. Several studies are looking on alternating high dose regimens with R-CHOP, the high dose drugs being cytarabine, methotrexate or both.
Christian H. Geisler, Front-line treatment of mantle cell lymphoma, haematol August 1, 2010 vol. 95 no. 8 1241-1243
Rémy Gressin et al,Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group Haematologica August 2010 95: 1350-1357